AZ, PTC collaborate in oncology

Thursday, June 30, 2011 09:59 AM

AstraZeneca and PTC Therapeutics are joining forces for cancer cures, using PTC's discovery/development technology platform, reported FierceBiotech.  AZ will front an undisclosed amount of cash to work on the first oncology target.

The platform, Gene Expression Modulation by Small Molecules (GEMS), helps researchers develop small-molecule drugs that can increase or decrease the expression of a specific protein by targeting its regulatory mechanisms.

PTC is in line for "significant" milestone payments in the deal, under which AZ gets global commercialization rights. PTC retains an option to participate in the development of select candidates. AstraZeneca will pay tiered royalties on worldwide net sales.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs